Lenalidomide and prednisone for myelofibrosis: Eastern Cooperative Oncology Group (ECOG) phase 2 trial E4903.

Blood
Ruben A MesaMartin S Tallman

Abstract

A multicenter Eastern Cooperative Group (ECOG) phase 2 trial assessed whether adding prednisone to lenalidomide would improve previously reported responses in persons with myelofibrosis (MF). Forty-eight subjects with anemia (42 evaluable) received lenalidomide, 10 mg/d, with a 3-month low-dose prednisone taper. Ten subjects received 3 months, and 25 received 6 months of therapy. Myelosuppression was the main toxicity with 88% with ≥ grade 3 hematologic toxicity and 45% ≥ grade 3 nonhematologic toxicity. There were responses in 10 subjects (23%) using the International Working Group for Myelofibrosis Research and Treatment (IWG-MRT)-defined clinical improvement of anemia in 8 (19%) and/or decreased spleen size in 4 (10%). Serial bone marrow analysis showed no resolution of disease-related fibrosis or angiogenesis. With a median follow-up of 2.3 years, 23 subjects are alive. Lenali-domide and prednisone for myelofibro-sis evaluated through a multicentered-cooperative group mechanism is only modestly active and myelosuppre-sive. This study was registered at http://clinicaltrials.gov as NCT00227591.

References

Jul 27, 2001·British Journal of Haematology·G BarosiM Marchetti
Jul 14, 2004·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·S A ScheyA G Dalgleish
Feb 11, 2005·The New England Journal of Medicine·Alan ListJerome B Zeldis
Apr 13, 2006·Blood·Ayalew TefferiHagop M Kantarjian
Aug 5, 2009·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Ayalew TefferiHagop M Kantarjian
Sep 2, 2009·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Alfonso Quintás-CardamaSrdan Verstovsek
Jan 7, 2010·American Journal of Hematology·Ruben A MesaAyalew Tefferi

❮ Previous
Next ❯

Citations

Apr 29, 2010·Current Hematologic Malignancy Reports·Ruben A Mesa
Jan 27, 2012·Current Hematologic Malignancy Reports·Giovanni BarosiVittorio Rosti
Mar 31, 2011·Nature Reviews. Clinical Oncology·Claudio TripodoStefano A Pileri
Feb 2, 2011·Nature Reviews. Drug Discovery·Alfonso Quintás-CardamaSrdan Verstovsek
Feb 2, 2012·Nature Reviews. Drug Discovery·Ruben A MesaPeter Kirkpatrick
Sep 6, 2011·Current Opinion in Oncology·Francisco Cervantes, Arturo Pereira
Dec 14, 2011·Hematology·Alessandro M Vannucchi
Dec 14, 2011·Hematology·Lionel Adès, Pierre Fenaux
Dec 10, 2013·Hematology·Olatoyosi Odenike
Jan 5, 2011·Blood·Ayalew Tefferi
May 31, 2011·Blood·Elias JabbourSrdan Verstovsek
Aug 3, 2012·Journal of Hematology & Oncology·Jasleen RandhawaSrdan Verstovsek
Jun 1, 2012·Future Oncology·Alessandro M VannucchiPaola Guglielmelli
Sep 6, 2014·Best Practice & Research. Clinical Haematology·Gunnar Birgegård
Mar 29, 2013·Wiener klinische Wochenschrift·Sonja BurgstallerHeinz Gisslinger
Jul 17, 2012·Leukemia & Lymphoma·Ruben A Mesa
Apr 11, 2015·Leukemia & Lymphoma·Brady L SteinSrdan Verstovsek
Feb 23, 2011·Leukemia & Lymphoma·Martha Q Lacy, Ayalew Tefferi
Feb 3, 2015·Leukemia & Lymphoma·Koji SasakiSrdan Verstovsek
Mar 22, 2013·Expert Opinion on Pharmacotherapy·Francisco Cervantes, Alejandra Martinez-Trillos
Apr 5, 2011·Expert Opinion on Pharmacotherapy·Giovanni BarosiAlessandro M Vannucchi
Sep 21, 2012·Expert Opinion on Investigational Drugs·Raoul TibesRuben A Mesa
Apr 28, 2011·Expert Opinion on Investigational Drugs·Alfonso Quintás-Cardama, Srdan Verstovsek
Nov 29, 2012·Expert Opinion on Emerging Drugs·Ehab Atallah, Srdan Verstovsek
Jun 7, 2012·Expert Opinion on Investigational Drugs·Ali Tabarroki, Ramon V Tiu
Feb 4, 2016·The Cancer Journal·Sonia CerquozziAyalew Tefferi
Jul 17, 2012·Pharmacology & Therapeutics·Beiqing Pan, Suzanne Lentzsch
Feb 19, 2016·Expert Review of Hematology·Francisco CervantesJuan Carlos Hernandez-Boluda
Jul 16, 2013·British Journal of Haematology·Jean-Christophe IanottoJean-Jacques Kiladjian
Nov 15, 2011·American Journal of Hematology·Kebede H BegnaAyalew Tefferi
Aug 6, 2015·Annals of Oncology : Official Journal of the European Society for Medical Oncology·A M VannucchiUNKNOWN ESMO Guidelines Committee
Aug 25, 2015·Clinical Lymphoma, Myeloma & Leukemia·Riad El Fakih, Uday Popat
Feb 14, 2012·Expert Opinion on Pharmacotherapy·Sonia ValletKlaus Podar
Sep 19, 2014·Blood·Francisco Cervantes
Mar 7, 2014·Journal of Hematology & Oncology·Raoul Tibes, Ruben A Mesa
Dec 5, 2014·Blood·Holly L Geyer, Ruben A Mesa
Feb 20, 2015·Hematology·Holly L Geyer, Ruben A Mesa
Aug 16, 2016·Revista brasileira de hematologia e hemoterapia·Paula de Melo Campos

❮ Previous
Next ❯

Related Concepts

Related Feeds

Anemia

Anemia develops when your blood lacks enough healthy red blood cells. Anemia of inflammation (AI, also called anemia of chronic disease) is a common, typically normocytic, normochromic anemia that is caused by an underlying inflammatory disease. Here is the latest research on anemia.